Clinical trial
ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve…
NCT02946463 · Alexion Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT02946463 |
|---|---|
| Title | ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Official title | A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Intervention type | Biological |
| Interventions | Ravulizumab, Eculizumab |
| Enrollment | 272 |
| Start date | Dec 12, 2016 |
| Primary completion | Feb 28, 2023 |
| Completion | Feb 28, 2023 |
| First posted | Oct 27, 2016 |
| Last update posted | May 14, 2024 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Estonia, France, Germany, Italy, Japan and 14 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: